Biohaven Ltd.
BHVN · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.14 | -0.01 | -0.02 |
| FCF Yield | -17.21% | -10.99% | -54.55% | -56.13% |
| EV / EBITDA | -3.81 | -6.59 | -0.79 | -0.87 |
| Quality | ||||
| ROIC | -189.09% | -93.58% | -92.72% | -219.07% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.81 | 0.52 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -75.19% | 1.18% | -130.80% | -86.61% |
| Safety | ||||
| Net Debt / EBITDA | 0.07 | 0.51 | 0.30 | 0.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |